<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587856</url>
  </required_header>
  <id_info>
    <org_study_id>MDS0620</org_study_id>
    <nct_id>NCT04587856</nct_id>
  </id_info>
  <brief_title>Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients</brief_title>
  <official_title>Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biological study for adult MDS patients who undergo HSCT procedure. Viable bone&#xD;
      marrow samples will be collected and cryopreserved from MDS patients before transplantation&#xD;
      and at clinical disease recurrence. CD34+ blast cells at disease relapse after HSCT will be&#xD;
      compared with CD34+ cells collected before transplant to study genomic and transcriptomic&#xD;
      changes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a biological study for adult MDS patients who undergo HSCT procedure.The research is&#xD;
      focused on the study of biological mechanisms of disease relapse after HSCT in MDS to provide&#xD;
      the rationale to develop pre-emptive strategies in patients with high risk of transplant&#xD;
      failure.&#xD;
&#xD;
      Viable bone marrow samples will be collected and cryopreserved from MDS patients before&#xD;
      transplantation and at clinical disease recurrence.&#xD;
&#xD;
      CD34+ blast cells at disease relapse after HSCT will be compared with CD34+ cells collected&#xD;
      before transplant by using Single-cell sequencing.&#xD;
&#xD;
      To study genomic and transcriptomic changes in CD34+ blast cells at disease relapse after&#xD;
      HSCT will be used TARGET-seq in parallel with unbiased whole-transcriptome analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD34+ blast cells modifications</measure>
    <time_frame>at 24 months</time_frame>
    <description>Difference in frequency distribution of CD34+ blast cells mutations between transplant and relapse.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Biological evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>evaluation of molecular changes in CD34+ blast cells at the time of relapse after allo-HSCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bone marrow withdrawal</intervention_name>
    <description>bone marrow samples evaluation</description>
    <arm_group_label>Biological evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MDS according to 2016 WHO criteria&#xD;
&#xD;
          -  Aged 18y or older&#xD;
&#xD;
          -  Patients who will receive allogeneic stem cell transplantation (HSCT)&#xD;
&#xD;
          -  Signed written informed consent according to ICH/EU/GCP and national local laws&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Second HSCT procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pellegrino Musto</last_name>
      <email>pellegrino.musto@uniba.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ististuto Clinico Humanitas - Rozzano - Uo Oncologia Medica Ed Ematologia</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo E Della Porta</last_name>
      <email>matteo.della_porta@hunimed.eu</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

